ReviewPharmaceuticals (Basel, Switzerland)2022
Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine.International journal of molecular sciences · 2026Review
- Gallibacterium anatis as an emerging pathogen in pet birds: biofilm formation contributes to treatment challenges and persistence.BMC microbiology · 2025Article
- Characteristic of Virulence and Parameters of Mixed Biofilm Formed by Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025Article
- Hostile Environments: Modifying Surfaces to Block Microbial Adhesion and Biofilm Formation.Biomolecules · 2025Review
- Pseudomonas aeruginosa biofilm: treatment strategies to combat infection.Archives of microbiology · 2025Review
- Assessing Biofilm at the Bedside: Exploring Reliable Accessible Biofilm Detection Methods.Diagnostics (Basel, Switzerland) · 2024Article
- Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies.Archives of microbiology · 2024Review
- Ciprofloxacin-Loaded Mixed Polymeric Micelles as Antibiofilm Agents.Pharmaceutics · 2023Article
- Lytic bacteriophages as alternative to overcoming antibiotic-resistant biofilms formed by clinically significant bacteria.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Biofilm is a crucial virulence factor for microorganisms that causes chronic infection. After biofilm formation, the bacteria present improve drug tolerance and multifactorial defense mechanisms, which impose significant challenges for the use of antimicrobials. This indicates the urgent need for new targeted technologies and emerging therapeutic strategies. In this review, we focus on the current biofilm-targeting strategies and those under development, including targeting persistent cells, quorum quenching, and phage therapy. We emphasize biofilm-targeting technologies that are supported by blocking the biofilm life cycle, providing a theoretical basis for design of targeting technology that disrupts the biofilm and promotes practical application of antibacterial materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.